BBI News Features Sanguine in Industry Story
In the Thursday, August 27, 1998, Volume 2, No. 34 edition of "Biomedical Business International Weekly" (BBI News), Managing Editor Don Long published a story about the blood substitute industry, including mentions of Northfield Laboratories, Hemosol and Sanguine Corporation.
Long says, "Headed by Dr. Thomas Drees, president and chief executive officer, Sanguine is developing a product called PHER-O2, a second generation version of the product that Drees helped develop while with Alpha Therapeutics."
Long added, "The improved PHER-O2 currently is being tested in collaboration with Battelle Memorial Research Institute with commercial rollout expected sometime in 2001." |
